Learn more Nominate Media 2013prize

The second annual Lupus Insight Prize, presented in a collaboration among the Alliance for Lupus Research (ALR), the Lupus Foundation of America (LFA) , and the Lupus Research Institute (LRI) will be awarded by the three organizations to recognize and honor an outstanding investigator with a documented record of creativity, innovation, and productivity. The researcher will also be someone who has made a novel insight in an area of research that is applicable to the pathogenesis or treatment of lupus and is judged to have a high likelihood of generating further advances by applying that insight to lupus.

The 2014 Lupus Insight Prize recipient will be awarded $200,000 to be used for research dedicated to advancing understanding of the genetic, environmental, molecular, immunologic or cellular aspects of lupus and/or its treatment. The Prize must be utilized within three years from the date it is awarded.

Nominations will be reviewed by members of an independent Selection Committee comprised of representatives of the three funding lupus organizations. The Committee will review nominations and award the Prize based on a variety of criteria, including academic achievements, creativity, insight, and potential for future advances that will impact people with lupus.

The full application must be submitted by the Nominator and the Candidate electronically by February 20, 2014 at 5 p.m. ET, The Prize recipient will be announced and honored publicly at the FOCIS Meeting on June 25, 2014 in a ceremony hosted by the three organizations.

Click here to nominate a Lupus Insight Prize Candidate TODAY!

Back to Top

RSVP

The Lupus Insight Prize will be awarded during the 2014 FOCIS Meeting. Please check here for more information about how to RSVP for this event.

Back to Top

Learn More

About the Prize Funds

The institution of the Prize recipient will receive $200,000 to be used at the discretion of the recipient scientist with the expectation that those funds will be applied to research dedicated to advancing understanding of the genetic, environmental, molecular, immunologic or cellular aspects of lupus and/or its treatment. The Prize can be transferred to another institution (within the U.S.) in the event

Nominate a Lupus Insight Prize Candidate

Back to Top

Nominate

Nominations for the Lupus Insight Prize should represent collaboration between the Nominator and Candidate. Nominations of basic, clinical, and translational scientists will be considered. Candidates can be investigators of any age or rank affiliated with an academic, biomedical, research, or government institution in the United States. Nominations will not be accepted for investigators working in the biotechnology or pharmaceutical industries. Additionally, Candidates may not already possess a grant award to pursue the aims described in the application for the Prize. Co-investigators or teams of investigators are not eligible for the Lupus Insight Prize.

How to Nominate

Nominators and Candidates should work together to prepare each Candidate's Letter of Nomination for The Lupus Insight Prize. Nominations of basic, clinical, and translational scientists will be considered. The Nominator should submit a two-page Letter of Nomination, describing the worthiness, expertise and achievements of the Candidate and specifically focus on the unique insight generated by the Candidate that might have an impact on advancing the future of lupus research. The letter of Nomination should clearly state the insight for which the candidate is being nominated.

  • a description of the novel hypothesis, innovative concept, or unusually creative experimental approach that will be applied to lupus by the Candidate
  • anticipated goal of the proposed project
  • potential impact of the proposed research on the field as a whole, as well as its potential to galvanize, change, and/or revolutionize lupus research or treatment

The Research Narrative should not be considered as a grant application, but should describe the applicant's unique insight and its potential to move lupus research forward. The Research Narrative should be a stand-alone document and cannot include any web links to additional materials. Appendices will not be accepted.

In addition to the Research Narrative, the Candidate should also submit a complete CV. Two blind letters in support of the Candidate (from people other than the Nominator) must also be solicited by the Candidate, and each must be submitted directly via proposalCENTRAL by the individual writing each letter. The application will not be considered complete without the two blind letters in support of the Candidate.

Each full application must be received electronically by February 20, 2014 at 5 p.m. ET via Altumís proposalCENTRAL online system at https://proposalcentral.altum.com/. Hard copies will not be accepted under any circumstances.

Back to Top

Lupus Organizations Unite to Stimulate Advances in Lupus Research Lupus Insight Prize to be awarded to Outstanding Scientist

NEW YORK, NY (December 18, 2013) Ė For the second year, the Alliance for Lupus Research (ALR), the Lupus Foundation of America (LFA) , and the Lupus Research Institute (LRI) will again join together to encourage scientific advances in lupus research. The Lupus Insight Prize, a novel collaborative initiative among the three organizations, will recognize and honor an outstanding investigator with a documented record of creativity, innovation, and productivity in lupus investigations, and with a high likelihood of generating further advances in the diagnosis and treatment of the disease. Lupus is an unpredictable and sometimes fatal autoimmune disease that affects an estimated 1.5 million Americans. The Lupus Insight Prize will be awarded annually by the sponsoring organizations.

The Request for Nominations will open December 18, 2013, with applications due by February 20, 2014. The 2014 Prize will be awarded at the Federation of Clinical Immunology Societies (FOCIS) annual meeting on June 25, 2014 by the three organizations.

"Our hope is that the continued collaboration between the Alliance for Lupus Research, the Lupus Foundation of America, and the Lupus Research Institute in the form of the Lupus Insight Prize is strong testimony to the dedication and commitment of these organizations to find a cure for lupus," said Mary K. Crow, M.D., Chair, ALR Scientific Advisory Board, Physician-in-Chief and Chair, Department of Medicine, The Hospital for Special Surgery. "The Prize encourages innovation. It furthers lupus research and allows for investigators to move the science and understanding of lupus forward," commented Gary S. Gilkeson, M.D., Chair, LFA Medical-Scientific Advisory Council. Peter Lipsky, M.D., LRI Scientific Advisory Board Member and Editor-in-Chief of Arthritis Research and Therapy adds, "This Prize recognizes important novel achievements in any scientific field that might impact lupus, and also provides funds to carry out the experiments that will lead to new insights about lupus and novel therapies for those who need it the most."

The Lupus Insight Prize recipient will be awarded $200,000 to be used for research dedicated to furthering understanding of the genetic, environmental, molecular, immunologic, or cellular aspects of lupus or its treatment. The Prize must be utilized within three years from the date awarded.

Lupus Insight Prize nominations will be reviewed by members of the independent Selection Committee, which is comprised of leading lupus scientific leaders from across the country and representatives of the three funding lupus organizations. The Selection Committee will review nominations and award the Prize based on several criteria, including academic achievements, creativity, insight, and potential for future advances that will improve the lives of people with lupus.

Nominations are open to investigators of any age or rank affiliated with an academic, biomedical, research, or government institution in the United States. Nominations will not be accepted for investigators working in the biotechnology or pharmaceutical industries. Additionally, nominees may not already possess a grant award to pursue the aims described in the Research Narrative. Co-investigators or teams of investigators are not eligible for the Lupus Insight Prize.

Instructions on how to submit a nomination for the Lupus Insight Prize and the complete guidelines are available at www.LupusInsightPrize.org. Nominators and Candidates should work together to prepare each Candidate's Letter of Nomination for The Lupus Insight Prize. Nominations of basic, clinical, and translational scientists will be considered. The Nominator should submit a two-page Letter of Nomination, describing the worthiness, expertise and achievements of the Candidate and specifically focus on the unique insight generated by the Candidate that might have an impact on advancing the future of lupus research. The Letter of Nomination should clearly state the insight for which the candidate is being nominated. The full application must be submitted no later than February 20, 2014 at 5 p.m. ET.

The Prize recipient will be announced and honored publicly in June of 2014 in a ceremony at the FOCIS 2014 Annual Meeting in Chicago, IL. This ceremony will include an opportunity for the award recipient to share plans about his/her lupus research. Details about the reception honoring the Prize recipient will be posted to www.LupusInsightPrize.org in the coming months.

Back to Top

Dr. Mark J. Shlomchik Receives Lupus Insight Prize Recognizing Outstanding Contribution in Lupus Research

JUNE 27, 2013

WASHINGTON, DC -- Mark J. Shlomchik, M.D., Ph.D., the incoming Chair of Immunology at the University of Pittsburgh, was honored Thursday as the first recipient of the Lupus Insight Prize, the first-of-a-kind award for use in innovative research on lupus, an unpredictable and sometimes fatal autoimmune disease that affects an estimated 1.5 million Americans. Dr. Shlomchik received the Prize during a formal ceremony at FOCIS 2013, the 13th Annual Meeting of the Federation of Clinical Immunology Societies in Boston.

The Prize is a collaborative initiative among the Alliance for Lupus Research, the Lupus Foundation of America, and the Lupus Research Institute to recognize and honor the achievements of an outstanding investigator in the field whose research efforts have a high likelihood of generating further advances in understanding the causes, biology, treatments, or cure of lupus.

"I would like to thank the three sponsoring organizations for bestowing this honor upon me," said Dr. Shlomchik. "Lupus is a very complex disease for which I have devoted much of my career. This award will enable me to further my research and make important contributions to understanding and treating this difficult disease."

With the award funds, Dr. Shlomchik will investigate the connection between the death of neutrophils, the body's most abundant white blood cells, and lupus. Many researchers believe lupus is the result of an abnormal immune response to dying cells. To fight infections, neutrophils use a molecule called NADPH oxidase. It was thought that this molecule may cause these neutrophils to die in a way that promotes an autoimmune response. However, to the surprise of most lupus researchers, Dr. Shlomchik discovered that lupus-prone mice that are missing this gene, have markedly worse diseaseóthe opposite of the original theory.

Dr. Shlomchik will create new animal models of lupus that produce neutrophils lacking NADPH oxidase to test how this molecule prevents animals from developing severe lupus. Because NADPH oxidase is turned on by infections, the work could help researchers understand the role infections might play in triggering lupus.

"We are pleased to collaborate with the other organizations to find better ways to manage lupus and, ultimately, to find a cure," said Ken Farber, President of the Alliance for Lupus Research. "By bringing together leaders in their fields, and those with a common focus, we have the opportunity to positively impact the well-being of the 1.5 million Americans with lupus."

"Dr. Shlomchik's work has provided insight into the underlying causes of lupus and has identified pathways for further research," said Sandra Raymond, President and CEO of the Lupus Foundation of America. "Continued support of these research efforts on lupus holds promise of generating further advances in the diagnosis and treatment of this devastating disease."

Lupus Research Institute President and CEO Margaret Dowd commented, "The Lupus Insight Prize recognizes Dr. Shlomchik's outstanding contributions to the field and supports his ability to continue his innovative work. Judging by the exceptional quality of Dr. Shlomchik's work, we can look forward to his further progress in developing novel approaches for new treatments."

Additional information about the Lupus Insight Prize and Dr. Shlomchik's work in lupus are available online at www.lupusinsightprize.org. Information on the application process for the 2014 Prize will be posted in the coming weeks.

Back to Top